dr. Eleonora Marostica

Journal Article
A1
open access

Pharmacokinetic analysis of modified-release metoprolol formulations : an interspecies comparison

Elien De Thaye, Anouk Vervaeck (UGent) , Eleonora Marostica (UGent) , Jean Paul Remon (UGent) , Jan Van Bocxlaer (UGent) , Chris Vervaet (UGent) and An Vermeulen (UGent)

(2017) EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. 97. p.135-142

Add to list

PK/PD modelling of the QT interval : a step towards defining the translational relationship between in vitro, awake Beagle dogs, and humans

Eleonora Marostica (UGent) , Karel Van Ammel, Ard Teisman, David Gallacher, Jan Van Bocxlaer (UGent) , Filip De Ridder, Koen Boussery (UGent) and An Vermeulen (UGent)

(2016) AAPS JOURNAL. 18(4). p.1000-1012

Add to list

Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies

Italo Poggesi, Maria Luisa Sardu, Eleonora Marostica (UGent) , Juthamas Sukbuntherng, Betty Y Chang, Jan de Jong, Xavier Woot de Trixhe, An Vermeulen (UGent) , Giuseppe De Nicolao, Susan Mary O'Brien, et al.

(2015) CLINICAL CANCER RESEARCH. 21(suppl. 17).

Add to list

Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities

Eleonora Marostica (UGent) , Karel Van Ammel, Ard Teisman, Koen Boussery (UGent) , Jan Van Bocxlaer (UGent) , Filip De Ridder, David Gallacher and An Vermeulen (UGent)

(2015) JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS. 42(6). p.659-679

Add to list

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies

Eleonora Marostica (UGent) , Juthamas Sukbuntherng, David Loury, Jan de Jong, Xavier Woot de Trixhe, An Vermeulen (UGent) , Giuseppe De Nicolao, Susan O'Brien, John C Byrd, Ranjana Advani, et al.

(2015) CANCER CHEMOTHERAPY AND PHARMACOLOGY. 75(1). p.111-121

Academic Bibliography

dr. Eleonora Marostica

Pharmacokinetic analysis of modified-release metoprolol formulations : an interspecies comparison

PK/PD modelling of the QT interval : a step towards defining the translational relationship between in vitro, awake Beagle dogs, and humans

Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies

Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies

Contents

Support

Contact